UTRxM1-18 / UTR Therap - LARVOL DELTA

UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers (GlobeNewswire) - "UTR Therapeutics...is pleased to announce a new milestone, the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers....UTRxM1-18 harnesses UTR’s proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with ultra-high precision and specificity....Our first-in-human Phase 1 trial is slated for 2026, pending FDA approval."

IND • New P1 trial • Solid Tumor